First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma-Reference-Cited by-同舟云学术

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma

Published:2012-07-18 Issue:2 Volume:119 Page:348-355
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wang Liang,Wang Zhi-hui,Chen Xiao-qin,Li Ya-jun,Wang Ke-feng,Xia Yun-fei,Xia Zhong-jun

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27752/fullpdf

Reference34 articles.

1. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma;Li;Clin Cancer Res.,2009

2. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project;Au;Blood.,2009

3. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies;Kim;Cancer Sci.,2009

4. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment;Kim;J Clin Oncol.,2000

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma;Hematology;2024-09-13

2. Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma;Chinese Medical Journal;2024-08-23

3. Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?;Leukemia & Lymphoma;2024-07-05

4. Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience;Acta Haematologica;2024-03-03

5. Advances and challenges of immunotherapies in NK/T cell lymphomas;iScience;2023-11